Nabriva Therapeutics

180 articles with Nabriva Therapeutics

• Nabriva Therapeutics Provides Corporate Update

  1/6/2023

  Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations.

• Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

  11/28/2022

  Nabriva Therapeutics plc announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF).

• Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

  11/10/2022

  Nabriva Therapeutics plc announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options.

• Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

  11/7/2022

  Nabriva Therapeutics plc today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022.

• Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

  9/15/2022

  Nabriva Therapeutics plc announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.

• Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis- Topline Data Expected First Quarter 2023 -

  8/11/2022

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of patient enrollment in its Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF).

• Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

  8/3/2022

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced its financial results for the three months ended June 30, 2022 and provided a corporate update.

• Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

  7/20/2022

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022.

• 

  Global Roundup: Hansa, OSE Nab New Funding, F-Star Links with Takeda

  7/20/2022

  Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.

• Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

  5/13/2022

  Nabriva Therapeutics plc today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.

• Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

  5/5/2022

  Nabriva Therapeutics plc announced its financial results for the three months ended March 31, 2022 and provided a corporate update.

• Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

  5/5/2022

  Nabriva Therapeutics plc announced that it agreed to an extension of its exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA, known as MSD outside the United States and Canada, to promote and distribute SIVEXTRO® in the United States through December 31, 2026.

• Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022

  5/2/2022

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, May 5, 2022.

• Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

  4/11/2022

  Nabriva Therapeutics plc (NASDAQ: NBRV), announced that the first patient was enrolled in a Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF).

• Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

  3/29/2022

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and year ended December 31, 2021 and provided a corporate update.

• Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

  3/15/2022

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2021 financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, March 29, 2022.

• Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022

  3/1/2022

  Nabriva Therapeutics plc announced that it has granted a non-statutory stock option to purchase an aggregate of 12,000 ordinary shares of Nabriva Therapeutics as an inducement to a newly hired employee.

• Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

  1/18/2022

  Nabriva Therapeutics plc announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders on January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021.

• Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

  1/14/2022

  Nabriva Therapeutics plc announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders on January 14, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021.

• Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

  1/10/2022

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced a business update and preliminary, unaudited financial results for the fourth quarter of 2021.